Individualized medicine enabled by genomics in Saudi Arabia

Muhammad Abu-Elmagd1,2,3,4*, Mourad Assidi1,2†, Hans-Juergen Schulten1, Ashraf Dallol1,2, Peter Natesan Pushparaj1, Farid Ahmed1, Stephen W Scherer1,5,6, Mohammed Al-Qahtani1

From 2nd International Genomic Medicine Conference (IGMC 2013)
Jeddah, Kingdom of Saudi Arabia. 24-27 November 2013

Abstract
The biomedical research sector in Saudi Arabia has recently received special attention from the government, which is currently supporting research aimed at improving the understanding and treatment of common diseases afflicting Saudi Arabian society. To build capacity for research and training, a number of centres of excellence were established in different areas of the country. Among these, is the Centre of Excellence in Genomic Medicine Research (CEGMR) at King Abdulaziz University, Jeddah, with its internationally ranked and highly productive team performing translational research in the area of individualized medicine. Here, we present a panorama of the recent trends in different areas of biomedical research in Saudi Arabia drawing from our vision of where genomics will have maximal impact in the Kingdom of Saudi Arabia. We describe advances in a number of research areas including; congenital malformations, infertility, consanguinity and pre-implantation genetic diagnosis, cancer and genomic classifications in Saudi Arabia, epigenetic explanations of idiopathic disease, and pharmacogenomics and personalized medicine. We conclude that CEGMR will continue to play a pivotal role in advances in the field of genomics and research in this area is facing a number of challenges including generating high quality control data from Saudi population and policies for using these data need to comply with the international set up.

Introduction
Leadership of the Kingdom of Saudi Arabia, is more conscious than ever of the necessity of establishing dedicated and long-term strategies that focus on the prevention of the effects of severe genetic disorders (most often due to consanguinity) and the impact of environmental changes (e.g., Dietary changes, toxins) on the general health of the Saudi society. As outlined in Figure 1, health policy planners and biomedical research scientists have conducted landscape surveys of the challenges facing the Saudi population, and formulated strategic objectives of how to move the health care research agenda forward with defined outcomes. Many of the decisions in investment in biomedical solutions for looming medical challenges are being grounded in establishing high-technology genomics and informatics-based centres that exploit the unique clinical and human resources available in the Middle Eastern countries, and in particular Saudi Arabia. International expertise is also being brought in through forward looking academic consultancies with universities and through new training initiatives.

In order to apply 21st century solutions in biomedical health research, at least three foundational genomic research initiatives are under way in the Gulf Cooperation Council (GCC), which include Kingdom of Saudi Arabia, Qatar, Oman, Bahrain, Kuwait and United Arab Emirates. These initiatives include, the catalogue of transmission genetics in Arabs (CTGA) [1] hosted by the Centre for Arab Genomic Studies in the United Arab Emirates, the Qatar Biobank Initiative [2] and the Saudi human genome program (SHGP) [3].

Established in 2003, the main purpose of the CTGA is to increase public and academic awareness for early diagnosis of genetic diseases in the Pan Arab population

* Correspondence: mabuelmagd@kau.edu.sa
† Contributed equally
1Centre of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, P.O. Box: 80216 Jeddah 21589, KSA
Full list of author information is available at the end of the article

© 2015 Abu-Elmagd et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
and to translate scientific knowledge into individualized medical treatment and management programs. As of January 2014, the CTGA online database curates over 1,000 disease phenotypes with a focus on the epidemiology in the Arab world, and it also maintains a record of nearly 250 associated disease loci. Many of the disease phenotypes studied are either more frequent (such as G6PD deficiency) or are regionally endemic, restricted to certain
tribal communities or even unique to consanguine families. Consanguinity, which is a main feature of the traditional Arabic culture (see below), leads to an increase of homozygosity for autosomal recessive genetic diseases which, from the perspective of research, can serve as an important repository for phenotype-genotype association studies [4]. The Qatar BioBank was initiated in 2010 aiming to take biosamples from Qatari population into repository to investigate diseases common to the domestic population [2]. Its ambitious goal is to serve as a driver for biomedical research inside and outside of Qatar. The SHGP intends to sequence the exomes and/or genomes of 100,000 Saudis within a period of five years taking advantage of the feasibility of next generation sequencing (NGS) [3]. In one of the large investments, NGS utilizing the Ion Proton technology (LifeTechnologies) has been allocated to the core facility of the SHGP in the capital Riyadh in addition to 15 planned satellite facilities across the Kingdom covering a substantial part of the 30 million nation’s populated areas. The satellites are established as collaborating institutions with self-adopted timelines and projects, which are led by on-site researchers independently from the SHGP headquarter.

Using the new genomic data, the SHGP is aiming to investigate a number of diseases, which are common or endemic in the country and have a strong genetic component such as diabetes, deafness, cardiovascular disease, neurodegeneration, cancer and inherited and Mendelian disorders (discussed below). Translational research aspects of this project include genetic counselling and in some instances further genetic testing of families where the underlying genetic mutations have been identified. For example, a number of genetic counselling services for inherited disorders like the pre-marital screening and genetic counselling program in Saudi Arabia for hemoglobinopathies and viral infections have been implemented [5]. Developing applications in pharmacogenomics research and personalized medicine are prospective objectives that may also arise from the SHGP. In addition, the aggregate genetic information offers the opportunity to perform genome wide association studies (GWAS) in a new dimensional scale. Such studies may shed light upon a number of polymorphic traits that are associated with certain diseases and are suspected to add to their penetrance which may gain special importance for endemic conditions like body mass index and obesity [6], or for acute diseases like cancer [7].

Our review is divided into five themes that we believe are most relevant for genomic technologies to have impact in Saudi Arabia. We ordered the themes based on our interpretation of the challenges unique to Saudi Arabia and the Middle East (Fig. 1). We believe the investment in research will have significant impact on our own health care systems and the lessons learned will also have an impact in other regions of the world, in particular as population migration expands and genetics becomes fully integrated into medical management for individuals and their family members [8]. Our vantage point is from working within the Centre of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University (KAU), Jeddah, Kingdom of Saudi Arabia (KSA). This dynamic organization is aiming to develop and apply the best practices in genomic medicine driven by world-class research programs (Fig. 2) to further the heath of citizens of Saudi Arabia and the world.

I. Congenital malformations in Saudi Arabia

Congenital malformations are identified as physical irreversible alterations induced during embryo formation that can be grouped into five categories: (1) single-gene anomalies, (2) chromosomal abnormalities, (3) maternal illness conditions during early pregnancy, (4) environmental and genetic inducers (e.g., teratogens), and (5) unknown causes, which account for ~50% of congenital malformations [9].

In Saudi Arabia, a number of studies were carried out to screen for congenital abnormalities in different regions of the kingdom (Fig. 3). In the Western province of Saudi Arabia, a high prevalence of major congenital abnormalities including cardiovascular, musculoskeletal, urinary and central nervous system (CNS) was reported [10]. Interestingly, this study showed that at least 38% of the parents of babies with congenital malformations were consanguineous. More supporting evidence from large multicentre studies conducted across Riyadh and the Eastern region revealed that first cousin marriage have a direct link with a number of congenital heart defects (CHD) [11-14]. Severe CHD were also reported in large studies in Al-Qassim (central region) with authors attributing the severity to the high rate of consanguinity [15,16]. These findings are not surprising since Saudi Arabia has the highest consanguinity among all middle eastern countries [17]. Based on Saudi Arabian regional distribution, South-Western and Northern provinces have the highest prevalence of CHD (Fig. 3)[18]. In Najran in South province, a significant high prevalence of hypothyroidism and hyperthyroidism associated with CHD were reported and attributed to high rate of consanguinity [19-21]. In Asir region in the South province, a high prevalence of a number of congenital malformations was detected in newly born babies and found to be linked to high consanguinity. Among these are gastrointestinal tract anomalies [22], CNS defects [23,24] and cardiovascular system defects [25]. All previous studies used hospital database analysis, however, the first community based study to measure the prevalence of CHD was carried out by Alqurashi, et al., 2007 [26]. This study showed that the central region had the highest CHD prevalence of 27 per 10,000 and the north-western was the least affected region with prevalence of 9 per 10 000 [26].
Figure 2 Centre of Excellence in Genomic Medicine Research (CEGMR) Multi-disciplinary platforms in biomedical research.

Figure 3 Regional prevalence of cardiac heart defects (CDH) in the Kingdom of Saudi Arabia.
A wide range of the CNS malformations including neural tube defects have been detected in different regions of Saudi Arabia with consanguinity appearing to be a major risk factor [23,24,27,28]. The mountainous geography of Saudi Arabia may also contribute to the high rate of congenital malformations since high altitude has been reported in other regions worldwide as a cause of congenital anomalies [29-31]. In Al-Taif city, known as a very high-altitude area, an increase in cardiovascular, urogenital, musculoskeletal, gastrointestinal, and cleft palate anomalies in addition to chromosomal abnormalities were reported [32].

Due to strong economic stability, obesity in Gulf countries in general and in Saudi Arabia and Kuwait in particular has become a high risk factor and a serious problem that reflects negatively on the these societies [6]. According to the Saudi Arabian national nutrition survey issued in 2007, the prevalence of obesity among women is 23.6% compared to 14.2% in men [33]. It has been reported that a mother’s body mass index of more than 30 is a predictor of a number of congenital malformations including cardiac, nervous system, facial and genitourinary tract defects [34]. Environmental factors and metabolic disorders are believed to induce congenital infections with toxoplasmosis, and cytomegalovirus that in turn result in inducing a number of congenital malformations including; microcephaly, seizures and intracranial calcification [35,36].

Different genomic research approaches to elucidate the causes of congenital anomalies in Saudi Arabia have recently begun to gain more attention. For example, a multi-level technology approach was used to unravel changes in gene expression profiling using array CGH, RNA-Seq and whole exome sequencing during early embryonic development that could be induced by air particulate pollution and pesticides.

II. Infertility and pre-implantation genetic diagnosis (PGD)
Infertility is a condition manifested by the biological incapacity of a couple to achieve a clinical pregnancy after at least one year of regular unprotected sexual intercourse [41]. The prevalence of this disease continues to rise and affects about 1 out of 6 couples in Saudi Arabia and worldwide [42,43]. Such infertility rates vary largely among countries and patient age [44]. The most common factors that could explain this severe decline in fertility are reproductive aging through the postponement of marriages, lifestyle, nutrition, the quality of health care services, and decrease in the child-seeking behaviour [45-47]. These factors are mainly due to the maternal age and to a lesser extent the paternal factors that could correlate with increased rates of gametes’ chromosome cohesion and therefore higher aneuploidy and chromosomal abnormalities in blastocysts [48-50].

There is an increase in the number of couples seeking infertility treatment services in assisted reproductive technologies (ART) clinics to help them to procreate. Despite valuable ART advantages, a remaining challenge is to increase qualitatively and quantitatively the in vitro fertilization (IVF) outcomes and reduce health care costs for both the mother and the offspring [51,52]. The gametes’ (spermatozoa and oocyte) quality has been recognized as the major limiting step and is therefore the target of numerous studies to improve their selection procedure [53-56], in order to make the elective single
embryo transfer (eSET) procedure more effective [57,58]. Chromosomal and some genetic mutations have been reported to underlie many of the challenges for obtaining successful embryo implantation and subsequent delivery of healthy babies [59-61].

In addition to the infertility challenges, Saudi society in particular is characterized as mentioned above by an extremely high-level of consanguinity. In fact, large proportions of marriages are still driven by ethnic or tribal considerations. The rate of consanguineous marriages is about 58% amongst them 60% were between first-degree cousins [12,17], which represents one of the highest in the Middle East and worldwide. In addition to the increase of the frequency of inherited recessive disorders, these consanguineous marriages have direct effects on some reproductive health parameters such as infertility rates, recurrent abortions, congenital disorders and neonatal death (Table 1) [4]. It should be highlighted that these genetic and chromosomal disorders’ rates are variable among regions inside Saudi Arabia. Additionally, these rates are exceptionally high in Saudi Arabia and Middle East in general compared to other regions in the world due to the burden of consanguinity and population inbreeding.

Given the challenges of high rates of consanguinity and disease in the Middle East and in Saudi Arabia, the Saudi ministry of health (MOH) decided in 2004 to make the premarital testing compulsory [5,62]. Such premarital examination includes mainly the basic blood tests, the hemoglobinopathies screening (Thalassemia & Sickle Cell Anaemia) and virology assays (Hepatitis B and C; AIDS). Despite these important measurements, PGD is still restricted to only few IVF clinics and it is the opinion of the authors that the level of awareness about infertility problems and genetic diseases needs to be given more attention especially in regions with high consanguinity as well as in rural and tribal areas. Investment in training and staffing in genetic counselling will also then be required.

The CEGMR aims to play a leading role in PGD by building translational research capacity. CEGMR is currently working in collaboration with KACST Centre of Innovation for Personalized Medicine (CIPM), Jeddah at KAU; the latter is being involved in delivering service through PGD screening for the larger Saudi population. CEGMR is currently developing new infertility screening methods using a specific panel of biomarkers with the primary aim being to reduce the comparatively high recurrence of abortions. For examples, new advances in technology have allowed the transfer of two embryos to the eSET preventing multiple pregnancies, which can disadvantage both the mother and the baby [63]. Similarly, a new project was recently initiated to establish an advanced premarital screening (APS) using state-of-the-art approaches with higher coverage (number of diseases) and accuracy. Once validated, such APS package will be presented to the MOH for consideration as an improvement of the existing test using advanced high throughput technologies.

Together, fertility and PGD screening programs as well as the APS package are excellent tools that are on line with the latest advances in the reproductive and developmental medicine field worldwide and are expected to significantly enhance the efficiency of both infertility diagnosis and treatment [64-66]. They will also facilitate detection and prevention of the transfer of most of the inherited disorders to the upcoming generations.

III. Cancer and genomic classifications in Saudi Arabia

All six GCC countries curate national cancer registries that provide statistics measures to the Gulf centre for cancer registration [67-70]. Remarkably, the national cancer registers of Bahrain, Kuwait, Oman, and Qatar are listed in a high incidence data quality category as assessed by the international agency for research on cancer (IARC) [71]. In comparison with USA, cancer data indicates a lower incidence rate for cancer in the Gulf region (Fig. 4); yet, a certain deviation of the frequency of the most common cancer types is observed [72]. For example, thyroid and liver cancer, as well as leukaemia and non-Hodgkin’s lymphoma (NHL) are relatively more common than in the USA (all races) [68,72]. Thyroid cancer is the second most frequent cancer in young women in the majority of the GCC countries [73,74]. Contrarily, prostate cancer is less frequent in the Gulf region, especially in Saudi Arabia [75]. In most common cancer types including thyroid and breast cancer, patients are several years younger at first diagnosis compared to Western countries [67,72,76,77]. Molecular genetics studies from the Gulf region have demonstrated that hereditary components like single nucleotide polymorphisms (SNPs) confer risk for breast [78] and thyroid cancer [79,80]. More specifically for the p53 codon, 72 polymorphism showed an association with early onset of breast cancer in Saudi women [81].

A high prevalence of childhood cancer in relation to adulthood cancer is observed in the GCC region. This discrepancy is in first instance attributed to the young population structure of the region [67,82]. Similar to Western countries, leukaemia and lymphomas including both Hodgkin’s lymphoma and NHL are among the most frequent paediatric cancers (Fig. 5). To provide specialized paediatric cancer care, the King Fahd National Centre for Children’s Cancer and Research, hosted by KFSH & RC, was established in 1997 in the Saudi capital Riyadh. The paediatric clinic, the largest in the region, performs approximately 70 stem cell transplantations per annum. One of the research areas of both institutions is focusing on the molecular genetics of diffuse B-cell lymphomas,
which are the most common subtype of extranodal NHL and occur with a comparably high prevalence in the Gulf region [83-85]. Notable findings include detection of clinically relevant biomarkers such as SKP2, XAIP, FOXM1, and MET in diffuse large B-cell lymphomas and detection of molecular mechanisms for NFκB in activated B-cell lymphomas [83,86-89]. For acute lymphoblastic leukaemia (ALL), a Saudi retrospective multicentre study revealed clinical characteristics similar to those found in developed countries; however, the authors noticed that standardization of patients’ care has to be improved [82]. Interestingly, an epidemiological survey in the Detroit area of USA revealed a higher incidence of leukaemia and bladder cancer in US-born males of Arab origin compared to non-Hispanic whites [90] indicating a possible involvement of inherited susceptibility factors in these malignancy types, as shown for other diseases like thyroid and breast cancer [79-81,91]. These findings emphasize the genetic heterogeneity of major cancer types, in which NGS may become the tool for personalized medicine intervention.

IV. Epigenetic explanations of idiopathic disease

A marked feature of cancer in the Kingdom of Saudi Arabia is the relatively young age of onset. The most common cancer type in Saudi Arabia is breast cancer comprising more than 16% of the cases seen at the largest oncology referral centre in the Kingdom, KFSH & RC [92]. Most of the affected females are below 50 years of age [92], which differs from Western countries where the age of onset is later [93]. Colon cancer is the most cancer type affecting Saudi males and here too the age of onset (40-65 years) [92] is less than seen in the west [93].
The reason for such age discrepancy is not entirely known. However, factors such as the early age of menarche (<12 years) and the use of exogenous progesterone and oestrogens could be suspected in the case of breast cancer [94]. The relatively young age of onset in this population could be explained by the interplay between common genetic susceptibility background substantiated by increased consanguinity and epigenetic aberrations. These factors are thought to be caused by shifts in life style being experienced in Saudi Arabia and in the Middle East in general in the past few decades. Similar life-style shifts are also seen in emerging economies such as India. Similar to Saudi Arabia, there is an increasing number of younger patients diagnosed with cancer every year in India [95]. The presence of a common genetic susceptibility factor(s) amongst Saudis is unknown. Interestingly, no significant associations of BRCA1 and BRCA2 mutations or SNP have been found in Saudi breast cancer cohorts [96,97]. However, there is an ongoing study to elucidate this further at CEGMR using high throughput technologies including Ion Torrent whole genome sequencing. In addition, our exome sequencing efforts of familial breast cancer cases have yet to reveal a common gene or mutation in the samples so far analysed [98]. Interestingly, every family sequenced thus far has a different underlying putative defective gene(s) precluding our ability to provide supporting evidence for the hypothesis that suggests the presence of a consanguinity-driven common genetic haplotype associated with increased susceptibility to breast cancer [98]. A more defined role for a “cancer susceptibility genome” will be determined following the conclusion of the SHGP project [99].

Epigenetics could therefore play a major role in the shift towards a younger age of onset. Life-style changes such as sleep and shift work patterns, diet and exercise can affect the genome in several ways and need to be considered. The circadian rhythm, mediated through an intricate network of transcriptional and post-translational mediators is necessary for maintaining a healthy homeostasis [100-102]. When the circadian rhythm is disrupted through sleep deprivation, global changes in gene expression can occur altering cellular behaviour. Methylation is a key mechanism for altering gene expression in response to sleep deprivation, such as what happens to the brain function [103]. The pleiotropic melatonin is the main sensor for light and it has cancer-protective effects through several mechanisms, including regulating estrogen pathway [104]. Interestingly, we have identified frequent hypermethylation of the melatonin receptor, MTNR1B, in a fraction of our cohort of breast cancer cases (35%) with significant association with histological grade I [105]. Such a result is intriguing and could implicate the epigenetic deregulation of key components of the circadian clock, which in turn, could potentiate cancer at an early age [100,101].

Sleep deprivation is not the only suspect behind the age shift observed. Aberrant metabolism is also likely to play a role. The incidence rates of the metabolic syndrome (obesity, high blood pressure, elevated fasting glucose...
levels, elevated cholesterol levels) in Saudi Arabia are reported to be among the highest in the world [106]. There is also emerging evidence of metabolic syndromes contributing to the increasing rates and age shift of cancer in Saudi Arabia. Our genome-wide methylation analysis of breast cancer has identified a role for the KLOTHO-FGF19-FGF23-FGFR4 signaling axis. FGF19 expression is elevated and is associated with a significantly shorter life expectancy of breast cancer patients of Saudi and Libyan descent [107]. The upregulation of FGF19 expression is coupled with high FGF23 and FGFR4 expression and frequent methylation of KLOTHO in the same cohort (Unpublished data). While a role for FGFR4 has been previously shown [108,109], implicating the metabolic hormones FGF19, FGF23 and KLOTHO in cancer is equally intriguing; the emerging question being if dysregulation of these genes may be a direct cause of carcinogenesis or more generally a symptom of metabolic health, which in itself predisposes to cancer at a significantly younger age? More work is warranted to shed light on the role of this metabolic axis in cancer because of its potential as an actionable target for treatment [110,111].

Other genes are inactivated by promoter hypermethylation. In colorectal cancer from Saudi Arabia, the methylation of the polycomb gene targets in the absence of CpG island methylator phenotype (CIMP) is a predictor of favourable prognosis [112]. Interestingly, we have identified a group of older patients with no detectable methylation in the genes analysed and yet displayed aggressive tumours that led to a significantly lower disease-specific survival rates [112]. The most frequent methylation event detected in breast cancer from Saudi cases is at the RASSF1A promoter, an event that is a potential predictor of poor prognosis [113]. However, the methylation frequency of other genes analysed in that study was lower than reported elsewhere, especially in the case of Estrogen Receptor-1 (ESR1) and Cadherin-1 (CDH1) methylation [113]. This could be attributed to the relatively early age of onset for the patients analysed, or to the presence of regional and ethnic-specific differences in gene regulation in breast cancer. BRCA1 methylation in blood from breast cancer patients could provide a potential mechanism for cancer susceptibility in the Saudi population and offer a promising tool for the detection of cancer predisposition [114]. Amplification of TNRC9, a common event in breast cancer from the MENA region, can directly result in the epigenetic silencing of BRCA1 expression [115]. Incidentally, SNPs in the TNRC9 locus have been shown to be significantly associated with breast cancer [116].

Other epigenetic lesions underlying cancer in Saudi Arabia could exist. Differential expression of miRNAs including hsa-mir-146a2, hsa-mir-196a2 and hsa-mir-499 are detected in peripheral blood of breast cancer patients [117]. Furthermore, polymorphisms identified in those miRNAs have been found to be significantly associated with breast cancer susceptibility [117]. A similar effect is observed in risk modification for prostate cancer in northern Indian populations [118]. Polymorphisms in hsa-mir-196a has been shown to be associated with increased risk for nasopharyngeal carcinoma in Chinese patients [119], and with increased risk for non-small cell lung carcinoma in the Korean population [120]. Conversely, these genetic variants do not seem to influence breast cancer risk or age of onset in German or Italian populations [121].

V. Pharmacogenomics and personalized medicine
Pharmacogenomics (PGx) is the study of the role of genetic polymorphisms in drug response [122,123]. PGx is a rapidly evolving field in particular due to the rapid advances in genotyping platforms and NGS technologies to scan the genome at increasing levels of resolution [124]. The interface of PGx and complex diseases including various types of cancers, understanding and managing serious adverse drug reactions (SADRs), and public health pharmacogenetics, are the major areas of investigation at CEGMR and elsewhere [124,125].

The potential opportunities emerging from PGx include, but not limited to, the prediction of personalized response to drugs, tailor-made prescriptions, reducing adverse drug reactions (ADRs), increasing the efficacy and reducing the toxicity of drugs, developing more robust and safer vaccines, monitoring and screening of specific diseases, as well as advancing research and development of novel drugs [122]. Pharmacogenomics (PGt) is the study of single genes that have significant influence on clinically actionable drugs [126].

In the past two decades, several drugs were primarily withdrawn from the USA market due to ADRs [125,127,128]. The ADRs are broadly categorized into Type A and B reactions [127]. Type A reactions are predictable, dose-dependent and constitute about 80% of ADRs [125,127]. The hypotension with anti-hypertensive treatment and incidences of bleeding in patients treated with Warfarin are some of the examples of Type A ADRs [125,127]. However, Type B reactions are termed as “idiosyncratic” or random ADRs observed mostly in genetically susceptible individuals [127]. Moreover, Type B reactions may potentially lead to SADRs that require either temporary or prolonged hospitalization and in some instances permanent disability or are even fatal [125,129]. Deciphering the genetic variations in populations [130], associated with Type B reactions using PGx strategies, could markedly reduce the healthcare budgets, promote drug discovery and the development of reliable and safer drugs [125,129].

The Cytochrome P450 (CYP450) super-family consists of functionally diverse groups of drug detoxifying
enzymes encoded by 57 genes and 5 pseudo genes, identified thus far, in the human genome [131,132]. The CYP450 enzymes are chiefly expressed in liver and facilitate the metabolism of drugs, xenobiotics, toxic pollutants, steroids, vitamin D, cholesterol metabolism and bile synthesis, retinoic acid, arachidonic acid and eicosanoids [132,133] by conjugating with functional groups and eventually removal from the body [132,134,135]. Members of the CYP450 super-family like CYP1, CYP2, and CYP3 are essential for the phase I metabolism of about 90% of all clinically applicable drugs [134-136]. The personalized variations in the expression of chief detoxifying CYP450 enzyme systems in humans, such as CYP1A2, CYP2C, CYP2D6, CYP2E1, CYP3A4 and CYP3A5, can influence the metabolism of a clinically relevant drug and the ADRs associated with its standard doses [124,135,136]. An array of factors such as the genetic polymorphisms, poor diet, endocrine dysregulation, epigenetic changes, acute and chronic liver diseases can critically influence the personalized variation in the expression of CYP450 system [135,137]. Besides, the CYP450 clinical phenotypes are classified based on individuals' ability to metabolize a particular drug as ultra-rapid metabolizers (UMs), Extensive Metabolizers (EMs), Intermediate Metabolizers (IMs) and poor metabolizers (PMs) [138,139]. The PMs have two non-functional alleles that decrease the expression of a particular CYP450 enzyme [136]; IMs have one functional allele and one heterozygous null allele for a CYP450 enzyme [136]. EMs have two functional homozygous alleles and may require higher concentrations of a therapeutic drug compared with IMs and PMs [136]. UMs have two or more copies of a functional CYP450 gene and metabolize the drug substrates rapidly and always require higher concentrations of drugs to achieve good therapeutic outcomes [136].

Genetic polymorphisms of CYP450 superfamily of genes greatly influence the efficacy, safety and the clinical outcome of a drug treatment [136]. CYP2D6 is one of the most important CYP450 enzyme required for the metabolism of more than 30% of therapeutically relevant drugs, including antidepressants and antipsychotics [138,139]. It is polymorphically expressed, and found to be absent in 1- 2% of Asians, 6 - 10% of Caucasians [139] and are classified as PMs [138,139]. Over 25% of Ethiopians and 2% of Caucasians are classified as CYP2D6 UMs [138,140]. In general, PMs of drugs have an increased risk of developing ADRs when compared to UMs and EMs. For example, codeine, a pro-drug, is converted to morphine by CYP2D6 enzyme to exert its analgesic properties [140]. Therefore, the efficacy of codeine was significantly reduced in individuals with CYP2D6 PMs [140]. On the other hand, the efficacy of codeine was markedly increased in CYP2D6 IMs and CYP2D6 UMs leading to drug toxicity in some individuals [140].

CYP2C subfamily of enzymes metabolizes about 20% of clinically relevant drugs including non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and oral anti-diabetic agents such as tolbutamide, glibenclamide, glimepiride and glipizide [141-143]. To date, more than 57 alleles of CYP2C9 have been reported [144] amongst which CYP2C9*2 and CYP2C9*3 alleles are the most prevalent in Caucasian as well as Asian populations and individuals carrying these polymorphisms exhibit reduced CYP2C9 activity [141]. An association was established between reduced expression of CYP2C9 and higher risk of bleeding episodes and upper-gastrointestinal (GI) bleeding in Warfarin-treated patients [136,145]. The alleles of CYP2C9 namely, CYP2C9*2 and CYP2C9*3 are responsible for reduced CYP2C9 enzyme activity leading to increased anti-coagulation [136]. These patients should be administered with lower dose of Warfarin to attain effective anti-coagulation, and diminish the possibility of bleeding episodes [136,145,146].

In Oman, the frequencies for CYP2C9*2 and CYP2C9*3 alleles were shown as 7.4% and 2.9% respectively [147,148]. In Egypt, the allelic frequencies of CYP2C9*2 and CYP2C9*3 alleles were estimated as 12% and 6% respectively [149]. In Lebanon, the allele frequencies for these two alleles were found to be 11.2% and 9.6%, respectively [148,150]. The frequencies of CYP2C9*2 and CYP2C9*3 alleles among Saudis in Al-Ahsa were about 13.4% and 2.3%, respectively [148]. In Riyadh, the frequencies for CYP2C9*2 and CYP2C9*3 alleles were reported to be 11.7% and 9.7% respectively [143]. The analysis of common genetic variants of the CYP2C9 subfamily in type 2 Diabetes mellitus (T2DM) patients in Jeddah showed that the allele frequencies of CYP2C9*2 and CYP2C9*3 were 25% and 9.3%, respectively (personal communication, Nehad Abdulqader Shaer and Ashraf Dallol). It was recently shown that the incidence of CYP2C9 polymorphisms in Saudi population was comparable to Caucasians; however, it was higher than Africans and Asians [151]. Saudi patients with CYP2C9*2 and CYP2C9*3 alleles had more adverse bleeding episodes and require 40% less Warfarin dose to cause effective anti-coagulation (Fig. 6) [151].

In December 2004, the United States food and drug administration (FDA) approved the drug metabolizing enzyme (DME) genotyping system from Roche named as AmpliChip™CYP450 array [152]. The AmpliChip P450 array is used in Affymetrix GeneChip microarray instrumentation system to identify a patient's CYP2D6 and CYP2C19 genotypes from genomic DNA isolated from whole blood sample [152]. Based on the CYP450 genetic test results, clinical evaluation and other lab tests as a reference, the clinician designs personalized treatment
options for patients to minimize the risk of ADRs and sub-optimal dose response [152]. It was estimated that about 25% of all prescribed drugs in the USA contain PGx labelling [136,153], for example, the anti-coagulant Warfarin with PGx indications of CYP2C9 genotype specific dosing [136,154]. The FDA has published a table of PGx biomarkers in drug labelling of about 135 therapeutically relevant drugs in the market [26,155].

Though the advancing technologies in genomics and bioinformatics rapidly steer PGx towards personalized therapy for patients in clinics, PGx tests are currently limited to evaluate the safety and therapeutic efficacy of drugs for thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement, human immunodeficiency virus, chronic myeloid leukaemia and gastrointestinal stromal tumours, ALL, colon, breast and lung cancers [156].

At present, the key challenges of personalized medicine include; achieving the goal of $1000 genome [157], increasing the speed of genome or exome sequencing by yet to be developed technologies [156], and making these platforms user friendly. Moreover, establishing dynamic PGx tools and databases [158-160], training physicians to apply PGx results to formulate preventive and personalized healthcare [161], and establishing privacy rules will be required to further the translational science [122,156]. At CEGMR, we are currently in the process of establishing custom-built PGx tools and databases as well as evaluating the PGx and toxicogenomics of several drugs used for the treatment of diseases afflicting Saudi population. Last, but perhaps most important, will be to, establish proper allele frequencies in populations from Saudi regions and others from across the globe [123,156].

**Discussion and summary**

All of the investments in equipment in genomics infrastructure, and bioinformatics at CEGMR aid in generating fundamental knowledge to facilitate effective decision making for individuals and families. Our primary objective is to generate the highest quality genomic data from patients and relevant family and population controls to enable opportunity for point-of-care, as well as iterative decision making based on the comparative medical data available. The advantage in the Saudi system is centralized medical care and shared experiences in families, which will also enable genome-based discoveries and treatments among families, physicians, and researchers [162].

We also recognize the importance of thoughtful deliberation on issues of societal awareness about consanguinity,
infertility, and stigma associated with some genetic disorders and malformations. Therefore, the authority has launched several education and outreach programs in hospitals and schools [163]. CEGMR will continue to launch proactive communication plans with stakeholders such as government, media, children with disabilities, charitable associations, and other society representatives. Coupled with research, will also be newer ethical consenting processes that are particularly conscience of the vast array of genetic findings (and their implications) that arise from genome scanning [164]. Much of the data will be amenable to confidentiality, protection and control using an informatics-based approach [165,166]. However, there remains an urgent need in Saudi Arabia for up to date policies that comply with international standards, which implement strict control and protection of privacy and public release of bio-specimens and data [166-168]. CEGMR will also continue to develop and implement new algorithms and databases enabling iterative dynamic interpretations of data in personalized health decision making [169-171].

Other considerations relevant to translational medicine in the Saudi system include making reproductive health and ART more accessible and affordable for the average Saudi citizen so this approach can further ease the current staggering impact congenital malformations and genetic disease are having on the health care system [41]. We believe that there is a need for a strategic plan to recommend the PGD for patients with hereditary genetic disorders and receiving IVF services in the Kingdom. There also needs to be proactive and clear policies on the use of the human Embryonic Stem Cells (hESCs) and these should be easily accessed by all who are interested in the human stem cells research.

Disclosures

The authors disclose no competing financial interests.

List of abbreviations

ADRs: Adverse Drug Reactions; ALL: Acute Lymphoblastic Leukaemia; APS: Advanced Preimplantation Screening; ART: Assisted Reproductive Technologies; ASR: Average Standardized Rates; CDH1: Cadherin-1; CEGMR: Centre of Excellence in Genomic Medicine Research; CGH: Comparative Genomic Hybridization; ChD: Congenital Heart Defects; CIMP: CpG Island Methylator Phenotype; CIPM: Centre of Innovation for Personalized Medicine; CNS: Central Nervous System; CTGA: Catalogue of Transmission Genetics in Arabs; DMD: Duchenne Muscular Dystrophy; DMIE: Drug Metabolizing Enzyme; EMs: Extensive Metabolizer; eSET: elective Single Embryo Transfer; ESR1: Estrogen Receptor-1; FADA: Food and Drug Administration; GI: Gastrointestinal; GCC: Gulf Cooperation Council; G6PD: Glucose-6-phosphate dehydrogenase; GWAS: Genome Wide Association Studies; HESCs: human Embryonic Stem Cells; IARC: International Agency for Research on Cancer; IARC: International Agency for Research on Cancer; IMs: Intermediate Metabolizers; IVF: in vitro Fertilization; KACST: King Abdullah University, P.O. Box: 80216 Jeddah 21589, KSA. 2KACST Technology Innovation Centre in Personalized Medicine at King Abdullah University (CIPM), P.O. Box: 80216 Jeddah 21589, KSA. 3School of Biological Sciences, University of East Anglia, Norwich, Norfolk, NR4 7TJ, UK. 4Zoology Department, Faculty of Science, Minia University, Minia, P.O. Box 61519, Egypt. 5The Centre for Applied Genomics and Program in Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Ontario, Canada. 6The Centre for Applied Genomics and Program in Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Ontario, Canada.

Authors’ details

1Centre of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, P.O. Box: 80216 Jeddah 21589, KSA. 2KACST Technology Innovation Centre in Personalized Medicine at King Abdullah University (CIPM), P.O. Box: 80216 Jeddah 21589, KSA. 3School of Biological Sciences, University of East Anglia, Norwich, Norfolk, NR4 7TJ, UK. 4Zoology Department, Faculty of Science, Minia University, Minia, P.O. Box 61519, Egypt. 5The Centre for Applied Genomics and Program in Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Ontario, Canada. 6The Centre for Applied Genomics and Program in Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Ontario, Canada.

Published: 15 January 2015

References

1. Tadmouri GO, Al Ali MT, Al-Haj Ali S, Al Khaja N. CTGA: the database for genetic disorders in Arab populations. Nucleic acids research 2006, 34(Database issue).D602-D606.
2. Qamar Biobank for Medical Research. [http://www.qatarbiobank.org.qa/].
3. Saudi Human Genome Program. [http://rc.kfscar.edu.sa/sgp/].
4. Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA. Consanguinity and reproductive health among Arabs. Reproductive health 2011, 6:17.
5. Memish ZA, Sauded MIY. Six-year outcome of the national prenatal screening and genetic counseling program for sickle cell disease and beta-thalassaemia in Saudi Arabia. Annals of Saudi medicine 2011, 31(3):229-235.
6. Ng SW, Zaghoul S, Ali HI, Harrison G, Popkin BM: The prevalence and trends of overweight, obesity and nutrition-related non-communicable diseases in the Arabian Gulf States. Obesity reviews : an official journal of the International Association for the Study of Obesity 2011, 12(1):1-13.
7. Forina P, Khaja NA, Al Mi, Hamzeh AR, Nair P, Innocenti F, Patrinos GP, Kricka LJ. Genomics into healthcare: the 5th pan arab human genetics conference and 2013 golden helix symposium. Human mutation 2014, 35(5):637-640.
8. Scherer SW: Genomics is the medium for 21st century biology. Genome / National Research Council Canada = Genome / Conseil national de recherches Canada 2012, 55(10).
9. Sheridan E, Wright J, Small N, Corry PC, Oddie S, Whibley C, Pertherick ES, Malik T, Pawson N, McKinney PA, et al. Risk factors for congenital anomaly in a multiethnic birth cohort: an analysis of the Born in Bradford study. Lancet 2013, 382(9901):1350-1359.
10. Fida NM, Al-Aama J, Nichols W, Nichols W, Alqahtani M. A prospective study of congenital malformations among live born neonates at a
Spina bifida in Saudi Arabia: is consanguinity among the Saudi Arabian population. *Annals of Saudi medicine*, 28(3):169-173.

11. Al-Muazmi M, Al-Salloum AA, Al-Herbish AS, Al-Rashid AM, Al Omar AA. Consanguinity and major genetic disorders in Saudi children: a community-based cross-sectional study. *Annals of Saudi medicine*, 2002, 22(1):78-87.

12. El-Jarvay NA, Al-Nuaim AA, Redha MA, El-Desouki MI, Al-Herbish AS, Al-Manser A, Al-Mohanna F, Al-Hales ZY. Estimation of modified concordance ratio in sib-pairs: effect of consanguinity on the risk of congenital heart diseases. *The international journal of biostatistics*, 2010, 6(1): Article 3.

13. Al-Nuaim AA, Al-Jurayyan NA, Al-Shehri A, Al-Nuaim AA, Al-Binali AM. Prevalence of congenital cardiac diseases at the province of Al-Qassim, Saudi Arabia. *Annals of Saudi medicine*, 2001, 21(1):22-28.

14. Shoukri MM, Donner A, Dessouky NA, Subhani S, Al-Joufan M, Al-Omrani A, Malik AA. Congenital anomalies in infants with congenital hypothyroidism: increased incidence in Najran province, Saudi Arabia. *Journal of tropical pediatrics*, 1996, 42(6):348-351.

15. Al-Nuaim AA, Al-Manser A, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

16. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

17. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

18. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

19. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

20. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

21. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

22. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.

23. Al-Nuaim AA, Al-Daouk NA, Al-Rayes A, Al-Nuaim AA, Al-Binali AM, Al-Mohanna F, Al-Hales ZY. Neonatal screening for congenital hypothyroidism in Riyadh: Analysis of six year's experience. *Annals of Saudi medicine*, 1996, 16(1):20-23.
55. Mehri S, Levi Setti PE, Greco K, Sakkas D, Martinez G, Patrizio P: Correlation between follicular diameters and flushing versus no flushing on oocyte maturity, fertilization rate and embryo quality. Journal of assisted reproduction and genetics 2014, 31(3):17-27.

56. Assidi M, Sirard M-A: Abnormalities in sperm chromatin structure and DNA fragmentation in assisted reproductive technologies: a systematic review. Reproduction 2012, 143(5):673-81.

57. Colls P, Escudero T, Fischer J, Cekleniak NA, Ben-Ozer S, Meyer B, Nepomnyashchaya YN, Artemov AV, Roumiantsev SA, Roumyantsev AG, Yuen RK, Merkoulovitch A, Macdonald JR, Vlasschaert M, Lo K, Grober E: The development of papillary thyroid cancer susceptibility in Middle Eastern population. BMC medical genetics 2013, 14(1):47.

58. Straughen JH, Salihu HM, Keith L, Petrozzino J, Jones C: Obligatory versus elective single embryo transfer in vitro fertilization. A population-based analysis of data from the U.K. Human Fertilisation and Embryology Authority. The Journal of reproductive medicine 2013, 58(3-4):95-100.

59. Hodes-Wertz B, Grifo J, Gharib S, Kaplan B, Laskin CA, Glassner M, Munne S: Idiopathic recurrent miscarriage is caused mostly by aneuploid embryos. Fertility and sterility 2012, 98(3):675-680.

60. Kochhar PK, Ghosh P: Reproductive outcome of couples with recurrent miscarriage and balanced chromosomal abnormalities. The journal of obstetrics and gynaecology research 2013, 39(1):113-20.

61. Lo Giacco D, Chianese C, Sanchez-Curbelo J, Bassas L, Ruiz P, Rajmil O, Sarguell J, Vives A, Ruiz-Castane E, Oliva R, et al: Clinical relevance of Y-linked CNV screening in male infertility: new insights based on the 8-year experience of a diagnostic genetic laboratory. European journal of human genetics : EJHG 2013.

62. Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, Milaat W, Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, Milaat W: Multiple pregnancies (births): an ongoing epidemic. Journal of oncology 2014, 31(1):61.

63. Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, Milaat W, Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, Milaat W: Potential breast cancer risk factors among Saudi women aged 30-49 years. Reproduction and genetics 2014, 39(1):74-80.

64. Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, Milaat W, Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, Milaat W: Reproductive factors and breast cancer susceptibility in Saudi Population. PloS one 2013, 8(12):e85541.

65. Al-Harbi T, Al-Manjomi F, Al-Harbi M, Al-Ghamdi H, Temmim L, Baker H, Ajarim D, Al-Dayel F, Al-Sanea O, Al-Naas M, Uddin S, et al: Cancer statistics. CancerStats. [http://www.cancerresearchuk.org/cancerstats/].

66. Al-Harbi T, Al-Manjomi F, Al-Harbi M, Al-Ghamdi H, Temmim L, Baker H, Ajarim D, Al-Dayel F, Al-Sanea O, Al-Naas M, Uddin S, et al: Cancer statistics. CancerStats. [http://www.cancerresearchuk.org/cancerstats/].

67. Al-Harbi T, Al-Manjomi F, Al-Harbi M, Al-Ghamdi H, Temmim L, Baker H, Ajarim D, Al-Dayel F, Al-Sanea O, Al-Naas M, Uddin S, et al: Cancer statistics. CancerStats. [http://www.cancerresearchuk.org/cancerstats/].

68. Al-Harbi T, Al-Manjomi F, Al-Harbi M, Al-Ghamdi H, Temmim L, Baker H, Ajarim D, Al-Dayel F, Al-Sanea O, Al-Naas M, Uddin S, et al: Cancer statistics. CancerStats. [http://www.cancerresearchuk.org/cancerstats/].
19-50 years in Jeddah: a case-control study. The Journal of the Egyptian Public Health Association 2013, 88(3):165-170.
95. PINK Indian Statistics. [http://www.breastcancerindia.net/bc/statistics/stati.htm].
96. El-Harith el HA, Abdel-Hadi MS, Steinmann D, Dork T: BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi medical journal 2002, 23(6):700-704.
97. Hasan TN, Shaif G, Syed NA, Alsaif MA, Alsaif AA, Alshatwi AA: Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area. Asian Pacific journal of cancer prevention 2013, 14(10):5661-5664.
98. Husein Sal, Merdad A, Ali-Maghrabi, Ashraf Dallol: Detection of rare single nucleotide variants affecting genes in the DNA repair pathways in hereditary breast cancer, BMC Genetics 2014, 15(Suppl 2):P100.
99. Human Genome Program. [http://rcf.nlm.nih.gov/igsp/].
100. El-Harith el HA, Abdel-Hadi MS, Steinmann D, Dork T: BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia, an emerging high-risk area. Asian Pacific journal of cancer prevention 2013, 14(10):5661-5664.
101. Jia Y, Lu Y, Wu K, Lin Q, Shen W, Zhu M, Huang S, Chen J: BRCA1 promoter in peripheral blood cells from cancer-free women. International journal of oncology 2011, 39(1):129-135.
102. Shan J, Dousou PA, Bakhru S, Al-Azwar EK, Ascierto ML, Sastry KS, Bedri S, Kizhakkyal A, Aigha Ii, Malek J, et al: TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness. Cancer research 2013, 73(9):2860-2869.
103. Shylu Mathew AM, Jaudah Al-Maghrabi, Ashraf Dallol: A Functional Polymorphism in MIR196A2 Is Associated with Risk and Progression of Nasopharyngeal Carcinoma in the Chinese Population. Genetic testing and molecular biomarkers 2014, 18(3):149-155.
104. Shylu Mathew AM, Jaudah Al-Maghrabi, Ashraf Dallol: identification frequent MTHR18 methylation in breast cancer following the application of high-throughput methylation analysis. BMC Genomics 2014, 15(Supplement 2).
105. Al-Daghri NM, Khan N, Alkhafri KM, Attas OS, Alohwar HA, Alothaman A, Vanhouptide PW: Selected dietary nutrients and the prevalence of metabolic syndrome in adult males and females in Saudi Arabia: a pilot study. Nutrients 2013, 5(11):4587-4604.
106. Al-Daghri NM, Khan N, Alkhafri KM, Attas OS, Alohwar HA, Alothaman A, Vanhouptide PW: Selected dietary nutrients and the prevalence of metabolic syndrome in adult males and females in Saudi Arabia: a pilot study. Nutrients 2013, 5(11):4587-4604.
107. Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd AM, de Carvalho MB, dos Santos M, Mercante AC, Gazito D, de Al-Harith el HA, Abdel-Hadi MS, Steinmann D, Dork T: BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia, an emerging high-risk area. Asian Pacific journal of cancer prevention 2013, 14(10):5661-5664.
108. Al-Daghri NM, Khan N, Alkhafri KM, Attas OS, Alohwar HA, Alothaman A, Vanhouptide PW: Selected dietary nutrients and the prevalence of metabolic syndrome in adult males and females in Saudi Arabia: a pilot study. Nutrients 2013, 5(11):4587-4604.
109. Jia Y, Lu Y, Wu K, Lin Q, Shen W, Zhu M, Huang S, Chen J: BRCA1 promoter in peripheral blood cells from cancer-free women. International journal of oncology 2011, 39(1):129-135.
135. Fisher CD, Lickteig AJ, Augustine LM, Range-Moore J, Jackson JP, Ferguson SS, Cherrington NJ: Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug metabolism and disposition: the biological fate of chemicals 2009, 37(10):267-294.

136. Bans JK: African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. Evolution, medicine, and public health 2013., 1: 118-134.

137. Frye RF, Zighelb NK, Matske GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, Branch RA: Liver disease selectively modulates cytochrome P450-mediated metabolism. Clinical pharmacology and therapeutics 2006, 80(3):235-245.

138. Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2011, 109(2):111-114.

139. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J: Allelic Isoforms found in the Chinese Population on the Metabolism of Cytochrome P450. The New england journal of medicine 2004, 351(27):2827-2831.

140. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

141. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2011, 109(2):111-114.

142. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

143. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2011, 109(2):111-114.

144. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

145. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2011, 109(2):111-114.

146. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

147. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

148. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

149. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

150. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

151. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

152. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

153. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

154. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

155. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

156. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

157. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

158. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

159. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

160. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

161. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

162. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.

163. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J, Branch RA, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, and disposition: the biological fate of chemicals 2013, 61(1):95-98.
181. Tabbara KF, Badr IA: Changing pattern of childhood blindness in Saudi Arabia. The British journal of ophthalmology 1985, 69(4):312-315.
182. Tabbara KF, El-Sheikh HF, Shawaf SS: Pattern of childhood blindness at a referral center in Saudi Arabia. Annals of Saudi medicine 2005, 25(1):18-21.
183. Al-Nozha MM, Al-Maalouq MA, Al-Mazrou YY, Al-Harthi SS, Aralaf MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, et al. Diabetes mellitus in Saudi Arabia. Saudi medical journal 2004, 25(11):1603-1610.
184. El-Hazmi MA, Warsy AS, Al-Swaleem AR, Al-Swaleem AM, Sulaimani R, Al-Meshari AA. Diabetes mellitus and impaired glucose tolerance in Saudi Arabia. Annals of Saudi medicine 1996, 16(4):381-385.
185. Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ: Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genetics in medicine: official journal of the American College of Medical Genetics 2007, 9(6):372-377.
186. Akhtar MS, Qawf F, Borgio JF, Albuali W, Suliman A, Nasserullah Z, Al-Jarrash S, Al-Ali A: Spectrum of alpha-thalassemia mutations in transfusion-dependent beta-thalassemia patients from the Eastern Province of Saudi Arabia. Hemoglobin 2013, 37(1):65-73.
187. Memish ZA, Owaiah TM, Saeedi MY: Marked regional variations in the prevalence of sickle cell disease and beta-thalassemia in Saudi Arabia: findings from the premarital screening and genetic counseling program. Journal of epidemiology and global health 2011, 1(1):61-68.
188. Abuzenadah AM, Hussein IM, Damanhour GA, FM AS, Gan MA, Chaudhry AG, Zaher GF, Al-Atmas A, Al-Qahthani MH: Molecular basis of beta-thalassemia in the western province of Saudi Arabia: identification of rare beta-thalassemia mutations. Hemoglobin 2011, 35(4):346-357.
189. El Mouzan MI, Al Awamy BH, Al Torki MT: Clinical features of sickle cell disease in eastern Saudi Arab children. The American journal of pediatric hematology/oncology 1990, 12(1):51-55.
190. Nasserullah Z, Alshammari A, Abbas MA, Abu-Khamseen Y, Qadri M, Jaffer SA, Wabel MA: Regional experience with newborn screening for sickle cell disease, other hemoglobinopathies and G6PD deficiency. Annals of Saudi medicine 2003, 23(6):354-357.
191. Al-Qurashi MM, El-Mouzan MI, Al-Herbish AS, Al-Salloum AA, Al-Omar AA: The prevalence of sickle cell disease in Saudi children and adolescents. A community-based survey. Saudi medical journal 2006, 27(10):1480-1483.
192. El-Hazmi MA, Al-Hazmi AM, Warsy AS: Sickle cell disease in Middle East Arab countries. The Indian journal of medical research 2011, 134(5):597-610.
193. Muzaffer MA: Neonatal screening of glucose-6-phosphate dehydrogenase deficiency in Yanbu, Saudi Arabia. Journal of medical screening 2005, 12(4):170-171.
194. Warsy AS, El-Hazmi MA: G6PD deficiency, distribution and variants in Saudi Arabia: an overview. Annals of Saudi medicine 2001, 21(3-4):174-177.